{"nctId":"NCT03552575","briefTitle":"The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI","startDateStruct":{"date":"2018-07-01","type":"ACTUAL"},"conditions":["Heart Failure"],"count":93,"armGroups":[{"label":"Sacubitril/valsartan","type":"EXPERIMENTAL","interventionNames":["Drug: sacubitril/valsartan"]},{"label":"Valsartan","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan"]}],"interventions":[{"name":"sacubitril/valsartan","otherNames":[]},{"name":"Valsartan","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Acute myocardial infarction (AMI) at least 3 months prior to recruitment\n\n  * Left ventricular ejection ≤40% as measured by transthoracic echocardiography\n  * Ability to provide written, informed consent\n  * Age ≥18 years\n  * Tolerance of a minimum dose of ACE inhibitor/ARB (ramipril 2.5mg BD or equivalent)\n  * Treatment with a beta-blocker unless not tolerated or contraindicated.\n\nExclusion Criteria:\n\n* Contraindication to CMR (ferrous prosthesis, implantable cardiac device or severe claustrophobia)\n\n  * Clinical and/or radiological heart failure (NYHA≥2)\n  * Symptomatic hypotension and/or systolic blood pressure \\<100mmHg\n  * eGFR \\< 30 mL/min/1.73m2 and/or serum potassium \\>5.2mmol/L\n  * Persistent/permanent atrial fibrillation\n  * History of AMI within last 3 months\n  * History of hypersensitivity or allergy to ACE-inhibitors/ARB\n  * History of angioedema\n  * Known hypersensitivity to the active study drug substances, contrast media or any of the excipients\n  * Obesity (where body girth exceeds MRI scanner diameter)\n  * Pregnancy, planning pregnancy, or breast feeding\n  * Inability to give informed consent or comply with study protocol\n  * Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x ULN at Visit 1, history of hepatic encephalopathy, history of oesophageal varices, or history of portacaval shunt\n  * History of biliary cirrhosis and cholestasis\n  * Active treatment with cholestyramine or colestipol resins\n  * Active treatment with lithium or direct renin inhibitor\n  * Participation in another intervention study involving a drug or device within the past 90 days (co-enrolment in observational studies is permitted)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Left Ventricular End Systolic Volume Index","description":"Change in indexed left ventricular end-systolic volume (LVESVI) measured by cardiac MR measured in ml/m2","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"6.6"},{"groupId":"OG001","value":"-2.0","spread":"7.3"}]}]}]},{"type":"SECONDARY","title":"Change in N-terminal Prohormone of B-type Natriuretic Peptide Levels","description":"measured in pg/ml","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39","spread":null},{"groupId":"OG001","value":"-21","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in High Sensitivity Troponin I Levels","description":"measured in ng/L","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Left Ventricular End-Diastolic Volume Index","description":"Change in indexed left ventricular end-diastolic volume (LVEDVI) measured by cardiac MR measured in ml/m2","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":"8.8"},{"groupId":"OG001","value":"-1.2","spread":"8.6"}]}]}]},{"type":"SECONDARY","title":"Change in Left Atrial Volume Index","description":"Change in indexed Left Atrial Volume (LAVI) measured by cardiac MR measured in ml/m2","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"9.0"},{"groupId":"OG001","value":"-0.8","spread":"11.7"}]}]}]},{"type":"SECONDARY","title":"Change in Left Ventricular Ejection Fraction","description":"Change in left ventricular ejection fraction (LVEF) measured by cardiac MR measured in percentage","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"3.4"},{"groupId":"OG001","value":"1.4","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Change in Left Ventricular Mass Index","description":"Change in indexed left ventricular mass (LVMI) measured by cardiac MR measured in grams/m2","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"4.9"},{"groupId":"OG001","value":"-1.1","spread":"5.0"}]}]}]},{"type":"SECONDARY","title":"Change in Patient Well Being as Assessed by Patient Global Assessment Questionnaire","description":"Change in patient well being as assessed by patient global assessment questionnaire which is a patient reported outcome measure that involves a patients own response to questions about their overall health and/or disease activity","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":47},"commonTop":["Worsening renal function or acute kidney injury","Symptomatic hypotension","Hyperkalaemia","Symptomatic hypotension with systolic blood pressure <90mmHg","Angioedema"]}}}